Co-Authors
This is a "connection" page, showing publications co-authored by Rita Nanda and Frederick Howard.
Connection Strength
5.474
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.746
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
Score: 0.708
-
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence. medRxiv. 2026 May 12.
Score: 0.243
-
Discordance of Radiologic and Pathologic Complete Response in Patients with Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy. Acad Radiol. 2026 04; 33(4):1466-1472.
Score: 0.237
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 12 01; 8(12):e2549109.
Score: 0.236
-
Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer. J Clin Oncol. 2025 Oct 20; 43(30):3322-3323.
Score: 0.232
-
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer. medRxiv. 2025 Aug 27.
Score: 0.232
-
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
Score: 0.223
-
Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry. JCO Oncol Adv. 2024; 1.
Score: 0.217
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
Score: 0.217
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 04 15; 130(8):1210-1220.
Score: 0.206
-
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
Score: 0.197
-
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. NPJ Breast Cancer. 2023 Apr 14; 9(1):25.
Score: 0.197
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
Score: 0.196
-
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer. Res Sq. 2023 Mar 16.
Score: 0.195
-
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. Expert Rev Anticancer Ther. 2022 12; 22(12):1325-1331.
Score: 0.191
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 11; 196(1):57-66.
Score: 0.188
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.174
-
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
Score: 0.062
-
K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
Score: 0.059
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
Score: 0.056
-
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2026 Jun; 32(4):641-647.
Score: 0.055
-
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer. J Oncol Pharm Pract. 2026 Jan; 32(1):62-70.
Score: 0.055
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
Score: 0.054
-
Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. JMIR Cancer. 2024 Jul 18; 10:e55438.
Score: 0.054
-
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 12; 104:9-15.
Score: 0.050
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.050
-
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. NPJ Breast Cancer. 2023 May 06; 9(1):33.
Score: 0.049
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
Score: 0.049
-
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
Score: 0.046